Hepion Pharmaceuticals Appoints Former Interim CEO Gary Stetz as Chief Financial Officer, Effective October 9, 2026

Hepion Pharmaceuticals, Inc. has appointed Gary Stetz as its Chief Financial Officer, effective October 9, 2026. The company’s board of directors approved the appointment of Stetz, who previously served as the company’s Interim Chief Executive Officer.

Stetz, 64, is a Certified Public Accountant with more than 35 years of experience across accounting, finance, business valuation and corporate governance. He currently serves as Managing Partner of Stetz, Belgiovine, Manwarren and Wallis P.C., an accounting, auditing, tax compliance and advisory services firm serving more than 1,000 corporate clients.

In addition to his accounting and advisory responsibilities, Stetz has served as Chief Executive Officer of President Street Global, LLC since August 2026. He was Interim CEO of Hepion Pharmaceuticals from March 2026 until October 2026 and has served on the company’s board of directors since March 2026.

Stetz also served as a director of Canton Strategic Holdings, Inc. from April 2025 to June 2026. His leadership experience includes founding Allegiance Community Bank and serving on the board of BCB Bancorp.

His appointment as Chief Financial Officer follows his recent interim leadership role at Hepion Pharmaceuticals and adds decades of financial, accounting and corporate governance experience to the company’s leadership team.